However, since 75% of enrolled patients had a diagnosis of ALCL (which is ubiquitously CD30+), and the study was not powered enough to demonstrate a PFS advantage for individual PTCL subtypes, these results can be considered practice changing only for ALCL [56]. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.